NCT00750334

A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS)

A Phase I, Open-Label, Dose-Finding and Food Effect Study of Oral Clofarabine in Previously Treated Adult Patients With Myelodysplastic Syndromes (MDS)

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Genzyme, a Sanofi Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will be used to determine the maximum tolerated dose of oral clofarabine when administered daily for 14 consecutive days repeated every 21 days.

Conditions

• Myelodysplastic Syndromes

Interventions

Type	Name	Description
DRUG	clofarabine	Drug given Daily x 14 days and 7 days of rest for 21 day cycle
DRUG	clofarabine	Drug given Daily X 14 days and 7 days of rest for 21 day cycle

Timeline

• Start date: 2008-09-01
• Primary completion: 2008-10-01
• Completion: 2008-10-01
• First posted: 2008-09-10
• Last updated: 2015-05-21

Locations

3 sites across 1 country: United States